<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00419146</url>
  </required_header>
  <id_info>
    <org_study_id>LA.01.07.0001</org_study_id>
    <secondary_id>01T-106 (Stanley M.R.I.,USA)</secondary_id>
    <nct_id>NCT00419146</nct_id>
  </id_info>
  <brief_title>Treatment of Schizophrenia With an Omega-3 Fatty Acid (EPA) and Antioxidants</brief_title>
  <official_title>A Multicentre, Placebo-controlled Trial of Eicosapentaenoic Acid (EPA) and Antioxidant Supplementation in the Treatment of Schizophrenia and Related Disorders</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Aker</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Diakonhjemmet Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Stanley Medical Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Laxdale Ltd</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Scandinavian Society for Psychopharmacology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shipowner Emil Stray's legacy</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Johanne and Einar Eilertsen's research fund</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Solveig and Johan P. Sommer's foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Josef and Haldis Andresen's legacy</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Oslo</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Norwegian University of Science and Technology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Oslo University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this trial is to study the effect of adding the omega-3 fatty acid EPA and/or
      Vitamins E + C to antipsychotic drugs in younger patients with schizophrenia and related
      psychoses.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objective:

      Study the effect of adding Ethyl-EPA and/or Vitamins E + C to antipsychotic drugs in younger
      patients with schizophrenia and related psychoses.

      Methods and material:

        -  Design: Multicentre, randomized, double-blind, placebo-controlled, fixed dose, 2x2
           factorial, add-on clinical trial.

        -  Sample:

             -  Patients with schizophrenia, schizoaffective disorder or schizophreniform disorder
                (DSM-IV); aged 18-40 years; less than 15 years since first psychotic
                symptoms;admitted to a psychiatric department within the previous 21 days before
                screening; speaks fluently a Scandinavian language;treated with antipsychotics;
                written informed consent;no known allergy to trial agents;no substance dependence
                (DSM-IV);no warfarin currently or anamnestic indicators of impaired haemostasis.
                Planned: 200 patients. Actually included: 99 intent-to-treat patients.

             -  Healthy controls: aged 18-40 years;no mental disorder (DSM-IV). Included: 20
                persons.

        -  Clinical assessments: Positive and Negative Syndrome Scale (PANSS) (main outcome
           variable). Self-report questionnaire. Adverse effects (UKURS). Neurocognitive assessment
           battery. Niacin skin flush test. General medical assessment.

        -  Blood samples: RBC fatty acids, S-α-tocopherol, F2-isoprostane (kits), monocyte mRNA
           Phospholipase A22 (PLA2) Gr4a and 6a (RT-PCR method), RBC Gr4a PLA2 concentration (ELISA
           technique), a range of other biochemical tests.

        -  Experimental treatment over 16 weeks: Ethyl-EPA 2 g/d or Placebo EPA and Vitamin E 364
           mg/d + Vitamin C 1000 mg/d or Placebo Antioxidants

        -  Statistics: Linear Mixed Model for longitudinal analyses of effects; other uni- and
           multivariate methods (SPSS 12.0 - PASW Statistics 18).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2001</start_date>
  <completion_date type="Actual">April 2004</completion_date>
  <primary_completion_date type="Actual">April 2004</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Positive and Negative Syndrome Scale (PANSS)- Total</measure>
    <time_frame>Baseline - 8 weeks - 16 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>PANSS Subscales Negative, Positive, General Psychopathology</measure>
    <time_frame>Weeks 0, 8, 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GLOBAL ASSESSMENT OF FUNCTIONING- Split Version (S-GAF)</measure>
    <time_frame>Weeks 0, 8, 16</time_frame>
    <description>(S-GAF)Symptom Scale (S-GAF)Function Scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>WONCA-COOP FUNCTIONAL HEALTH ASSESSMENT CHARTS</measure>
    <time_frame>Weeks 0, 8, 16</time_frame>
    <description>5 scales</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NIACIN SKIN FLUSH TEST</measure>
    <time_frame>Weeks 0, 8, 16</time_frame>
    <description>2 concentrations of niacin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>THE UKU SIDE EFFECT RATING SCALE (USERS)</measure>
    <time_frame>Weeks 0,4,8,12,16</time_frame>
    <description>Sum of scores
Patients with side effects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SERIOUS ADVERSE EVENTS</measure>
    <time_frame>Weeks 0,4,8,12,16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CONCOMITANT ANTIPSYCHOTIC MEDICATION</measure>
    <time_frame>Weeks 0,4,8,12,16</time_frame>
    <description>Defined Daily Doses (ATC/WHO)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Kimura Recurring Recognition Figures Test</measure>
    <time_frame>Weeks 0, 16</time_frame>
    <description>A sub-sample of patients. For logistic reasons, only some study sites could participate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hopkins Verbal Learning Test.</measure>
    <time_frame>Weeks 0, 16</time_frame>
    <description>A sub-sample of patients. For logistic reasons, only some study sites could participate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Continuous Performance Test</measure>
    <time_frame>Weeks 0, 16</time_frame>
    <description>A sub-sample of patients. For logistic reasons, only some study sites could participate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hopkins Verbal Learning Test</measure>
    <time_frame>Weeks 0, 16</time_frame>
    <description>A sub-sample of patients. For logistic reasons, only some study sites could participate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Paced Auditory Serial Addition Test</measure>
    <time_frame>Weeks 0, 16</time_frame>
    <description>A sub-sample of patients. For logistic reasons, only some study sites could participate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stroop Test</measure>
    <time_frame>Weeks 0, 16</time_frame>
    <description>A sub-sample of patients. For logistic reasons, only some study sites could participate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Digit Span</measure>
    <time_frame>Weeks 0, 16</time_frame>
    <description>A sub-sample of patients. For logistic reasons, only some study sites could participate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Letter - Number Task</measure>
    <time_frame>Weeks 0,16</time_frame>
    <description>A sub-sample of patients. For logistic reasons, only some study sites could participate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Semantic and Category Fluency</measure>
    <time_frame>Weeks 0, 16</time_frame>
    <description>A sub-sample of patients. For logistic reasons, only some study sites could participate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body Mass Index</measure>
    <time_frame>Weeks 0, 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood pressure - systolic, diastolic</measure>
    <time_frame>Weeks 0, 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart rate</measure>
    <time_frame>Weeks 0, 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Albumin</measure>
    <time_frame>Weeks 0, 16</time_frame>
    <description>Serum</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urate</measure>
    <time_frame>Weeks 0, 16</time_frame>
    <description>Serum</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucose</measure>
    <time_frame>Weeks 0, 16</time_frame>
    <description>Serum - fasting</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cholesterol</measure>
    <time_frame>Weeks 0, 16</time_frame>
    <description>Serum - fasting</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Triglycerides</measure>
    <time_frame>Weeks 0, 16</time_frame>
    <description>Serum - fasting</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fatty acids in red blood cells</measure>
    <time_frame>Weeks 0, 16</time_frame>
    <description>The concentrations of long-chain (C14-18) and very long-chain (C20-24)fatty acids in erythrocytes were measured. Fasting condition.
We selected DGLA, AA, EPA, DHA, total omega-3 Polyunsaturated Fatty Acids (PUFA), total omega-6 PUFA, PUFA and LCPUFA (long-chain PUFA) as outcome measures.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Alpha-tocopherol adjusted for [triglycerides]+[cholesterol].</measure>
    <time_frame>Weeks 0, 16</time_frame>
    <description>Serum</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total antioxidant status</measure>
    <time_frame>Weeks 0, 16</time_frame>
    <description>Serum</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Malondialdehyde</measure>
    <time_frame>Weeks 0, 16</time_frame>
    <description>Also called &quot;TBARS&quot;. Serum</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>F2-isoprostane (8-epiPGF2-alpha)</measure>
    <time_frame>Weeks 0, 16</time_frame>
    <description>Serum</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cytosolic PLA2 group IV in red blood cells(ELISA method)</measure>
    <description>Omitted from stastical analyses because of problems with the pre-analytic procedure (treatment the of blood)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gene expression of mRNA for Phospholipase A2 (PLA2) groups IVa and VIa in monocytes.</measure>
    <time_frame>Weeks 0, 16</time_frame>
    <description>Whole blood</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Corpuscular Haemoglobin Concentration (MCHC)</measure>
    <time_frame>Weeks 0, 16</time_frame>
    <description>Whole blood</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Corpuscular Volume (MCV)</measure>
    <time_frame>Weeks 0, 16</time_frame>
    <description>Whole blood</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>C- Reactive Protein (CRP)</measure>
    <time_frame>Weeks 0, 16</time_frame>
    <description>Plasma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Haemoglobin</measure>
    <time_frame>Weeks 0, 16</time_frame>
    <description>Whole blood</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Leukocytes</measure>
    <time_frame>Weeks 0, 16</time_frame>
    <description>Whole blood</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Calcium</measure>
    <time_frame>Weeks 0, 16</time_frame>
    <description>Serum</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sodium</measure>
    <time_frame>Weeks 0, 16</time_frame>
    <description>Serum</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Potassium</measure>
    <time_frame>Weeks 0, 16</time_frame>
    <description>Serum</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ferritin</measure>
    <time_frame>Weeks 0,16</time_frame>
    <description>Serum</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Free thyroxin (T4)</measure>
    <time_frame>Weeks 0, 16</time_frame>
    <description>Serum</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Thyroid Stimulating Hormone (TSH)</measure>
    <time_frame>Weeks 0, 16</time_frame>
    <description>Serum</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">99</enrollment>
  <condition>Schizophrenia</condition>
  <condition>Schizophreniform Disorders</condition>
  <condition>Schizoaffective Disorder</condition>
  <condition>Psychotic Disorders</condition>
  <arm_group>
    <arm_group_label>Ethyl EPA (active) and Vitamins E + C (active)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Ethyl EPA (active) and Vitamins E+C (placebo)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Ethyl EPA (placebo) and Vitamins E+C (active)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Ethyl EPA (placebo) and Vitamins E+C (placebo)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ethyl-eicosapentaenoic acid (EPA)</intervention_name>
    <description>Capsules, 2 g per day for 16 weeks</description>
    <arm_group_label>Ethyl EPA (active) and Vitamins E + C (active)</arm_group_label>
    <arm_group_label>Ethyl EPA (active) and Vitamins E+C (placebo)</arm_group_label>
    <other_name>Provided by Laxdale Ltd., Scotland, UK</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vitamins E + C</intervention_name>
    <description>RRR-alpha-tocopherol 392 mg + slow-release ascorbic acid 1000 mg per day, for 16 weeks</description>
    <arm_group_label>Ethyl EPA (active) and Vitamins E + C (active)</arm_group_label>
    <arm_group_label>Ethyl EPA (placebo) and Vitamins E+C (active)</arm_group_label>
    <other_name>CellaVie (Ferrosan AS, Denmark)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Etyl EPA (placebo)</intervention_name>
    <description>Paraffin oil. Capsules, each 0.5 g.</description>
    <arm_group_label>Ethyl EPA (placebo) and Vitamins E+C (active)</arm_group_label>
    <other_name>Placebo EPA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Vitamins E+C (placebo)</intervention_name>
    <description>Tablets containing dicalciumphosphate</description>
    <arm_group_label>Ethyl EPA (active) and Vitamins E+C (placebo)</arm_group_label>
    <arm_group_label>Ethyl EPA (placebo) and Vitamins E+C (placebo)</arm_group_label>
    <other_name>Placebo CellaVie, provided by Ferrosan AS, Denmark</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with schizophrenia, schizophreniform disorder or schizoaffective disorder
             (DSM-IV)

          -  Admitted to a psychiatric hospital/department within the previous twenty-one days
             before screening

          -  Less than fifteen years, in retrospect, since first psychotic symptoms (DSM-IV 295,
             criteria A,1-4)

          -  Age 18-40 years

          -  Speaks fluently a Scandinavian language

          -  A written informed consent must be obtained before any trial-related activities

        Exclusion Criteria:

          -  A diagnosis of substance dependence (DSM-IV)

          -  Known allergy to study medication

          -  Currently taking warfarin or having anamnestic indicators of impaired haemostasis
             (profuse bleeding, except epistaxis)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Håvard Bentsen, MD PhD</last_name>
    <role>Study Director</role>
    <affiliation>Aker University Hospital (-2004), Diakonhjemmet Hospital (2004-)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Odd Lingjærde, MD PhD</last_name>
    <role>Study Chair</role>
    <affiliation>University Hospital, Aker</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Aker University Hospital</name>
      <address>
        <city>Oslo</city>
        <zip>0320</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <verification_date>August 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 5, 2007</study_first_submitted>
  <study_first_submitted_qc>January 5, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 8, 2007</study_first_posted>
  <last_update_submitted>January 3, 2011</last_update_submitted>
  <last_update_submitted_qc>January 3, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 4, 2011</last_update_posted>
  <keyword>Schizophrenia</keyword>
  <keyword>Schizophreniform disorders</keyword>
  <keyword>Schizoaffective disorder</keyword>
  <keyword>Psychotic disorders</keyword>
  <keyword>Randomized Controlled Trials</keyword>
  <keyword>Longitudinal Studies</keyword>
  <keyword>Fatty Acids, Omega-3</keyword>
  <keyword>Eicosapentaenoic Acid</keyword>
  <keyword>Vitamins</keyword>
  <keyword>Antioxidants</keyword>
  <keyword>Ascorbic Acid</keyword>
  <keyword>Alpha-Tocopherol</keyword>
  <keyword>Placebos</keyword>
  <keyword>Antipsychotic Agents</keyword>
  <keyword>Oxidative Stress</keyword>
  <keyword>Fatty Acids, Unsaturated</keyword>
  <keyword>Phospholipases</keyword>
  <keyword>Niacin</keyword>
  <keyword>Adverse effects</keyword>
  <keyword>Delusions</keyword>
  <keyword>Hallucinations</keyword>
  <keyword>Neuropsychological Tests</keyword>
  <keyword>Attention</keyword>
  <keyword>Memory</keyword>
  <keyword>Hypertriglyceridemia</keyword>
  <keyword>Models, Statistical</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Schizophrenia</mesh_term>
    <mesh_term>Psychotic Disorders</mesh_term>
    <mesh_term>Mental Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin E</mesh_term>
    <mesh_term>Tocopherols</mesh_term>
    <mesh_term>Tocotrienols</mesh_term>
    <mesh_term>alpha-Tocopherol</mesh_term>
    <mesh_term>Ascorbic Acid</mesh_term>
    <mesh_term>Antioxidants</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

